6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo(4,3-a)pyridine sulfate | 668981-07-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo(4,3-a)pyridine sulfate
• 英文别名: 4-(2,5-Difluorophenyl)-5-(3-propan-2-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-1,3-oxazole;sulfuric acid
• CAS: 668981-07-5
• 化学式: C₁₈H₁₄F₂N₄O*H₂O₄S
• 分子量: 438.412
• InChiKey: AEMJYTPFSXPCDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  139
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4] triazolo [4,3-a] pyridine 在 硫酸 作用下， 以 丙酮 为溶剂， 反应 12.0h， 生成 6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo(4,3-a)pyridine sulfate
  参考文献：
  名称：

  Alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines

  摘要：

  本发明涉及一种新型烷基-［4-(二氟苯基)-噁唑-5-基］-三唑-吡啶类化合物，其中包括用于制备它们的中间体、含有它们的制药组合物以及它们在医学上的应用。本发明的化合物是MAP激酶的有效抑制剂，特别是p38激酶。它们在治疗炎症、骨关节炎、类风湿性关节炎、癌症、脑卒中或心肌梗塞的再灌注或缺血、自身免疫性疾病和其他疾病中有用。

  公开号：

  US20040092547A1

文献信息

• Alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
  申请人：Pfizer Inc

  公开号：US20040092547A1

  公开（公告）日：2004-05-13

  The present invention relates to novel alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

  本发明涉及一种新型烷基-［4-(二氟苯基)-噁唑-5-基］-三唑-吡啶类化合物，其中包括用于制备它们的中间体、含有它们的制药组合物以及它们在医学上的应用。本发明的化合物是MAP激酶的有效抑制剂，特别是p38激酶。它们在治疗炎症、骨关节炎、类风湿性关节炎、癌症、脑卒中或心肌梗塞的再灌注或缺血、自身免疫性疾病和其他疾病中有用。
• Novel crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine
  申请人：Pfizer Inc

  公开号：US20040143119A1

  公开（公告）日：2004-07-22

  The present invention relates to novel crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-a]pyridine to pharmaceutical compositions containing such crystal forms and to methods of treatment. 3-Isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-a]pyridine is a potent inhibitor of MAP kinases, preferably p38 kinase (MAPK14/CSBP/RK kinase). 3-Isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-a]pyridine is useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

  本发明涉及3-异丙基-6-[4-(2,5-二氟苯基)-噁唑-5-基]-[1,2,4]三唑-[4,3-a]吡啶的新结晶形式，以及含有这种晶体形式的制药组合物和治疗方法。3-异丙基-6-[4-(2,5-二氟苯基)-噁唑-5-基]-[1,2,4]三唑-[4,3-a]吡啶是MAP激酶的有效抑制剂，优选为p38激酶（MAPK14/CSBP/RK激酶）。3-异丙基-6-[4-(2,5-二氟苯基)-噁唑-5-基]-[1,2,4]三唑-[4,3-a]吡啶在治疗炎症、骨关节炎、类风湿性关节炎、癌症、中风或心脏病的再灌注或缺血、自身免疫性疾病和其他疾病方面有用。
• Novel processes and intermediates for preparing triazolo-pyridines
  申请人：Pfizer Inc.

  公开号：US20040053959A1

  公开（公告）日：2004-03-18

  The present invention relates and intermediates to a novel process for preparing triazolo-pyridines of the formula I 1 wherein R 1 is selected from the group consisting of hydrogen, (C 1 -C 6 )alkyl or other suitable substituents; R 3 is selected from the group consisting of hydrogen, (C 1 -C 6 )alkyl or other suitable substituents; s is an integer from 0-5; R 4 is hydrogen or a suitable substituent and to intermediates for their preparation. The compounds prepared by the methods of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

  本发明涉及一种制备式I1中的三唑吡啶的新工艺，其中R1选自氢、(C1-C6)烷基或其他适当取代基组成的群体；R3选自氢、(C1-C6)烷基或其他适当取代基组成的群体；s是0-5的整数；R4是氢或适当的取代基，以及其制备的中间体。通过本发明的方法制备的化合物是MAP激酶，特别是p38激酶的有效抑制剂。它们在治疗炎症、骨关节炎、类风湿性关节炎、癌症、脑卒中或心脏病发作的再灌注或缺血、自身免疫性疾病和其他疾病方面有用。
• Di and trifluoro-triazolo-pyridines anti-inflammatory compounds
  申请人：Pfizer Inc.

  公开号：US20040053958A1

  公开（公告）日：2004-03-18

  The present invention relates to novel triazolo-pyridines of the formula I 1 wherein R 1 is fluoro; s is an integer from two to three; R 2 is (C 3 -C 6 )cycloalkyl optionally substituted by one or two moieties independently selected from the group consisting of halo, (C 1 -C 4 )alkyl, hydroxy, (C 1 -C 6 )alkoxy and (C 1 -C 6 )alkyl-(C═O)—O—; or R 2 is (C 1 -C 6 )alkyl optionally substituted by one or two moieties independently selected from the group consisting of halo, (C 1 -C 6 )alkyl, hydroxy, (C 1 -C 6 )alkoxy and (C 1 -C 6 )alkyl-(C═O)—O—; with the proviso that said compound of formula I cannot be 6-[4-(2,4-Difluoro-phenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine; or 6-[4-(3,4-Difluoro-phenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine; to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, repurfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

  本发明涉及式I1的新型三唑啉-吡啶化合物，其中R1为氟；s为2至3的整数；R2为（C3-C6）环烷基，可选地被一或两个基团独立地选自卤素、（C1-C4）烷基、羟基、（C1-C6）烷氧基和（C1-C6）烷基-(C═O)-O-；或者R2为（C1-C6）烷基，可选地被一或两个基团独立地选自卤素、（C1-C6）烷基、羟基、（C1-C6）烷氧基和（C1-C6）烷基-(C═O)-O-；但式I化合物不能是6-[4-(2,4-二氟苯基)-噁唑-5-基]-3-异丙基-[1,2,4]三唑啉[4,3-a]吡啶；或6-[4-(3,4-二氟苯基)-噁唑-5-基]-3-异丙基-[1,2,4]三唑啉[4,3-a]吡啶；本发明化合物是MAP激酶的有效抑制剂，优选为p38激酶。它们可用于治疗炎症、骨关节炎、类风湿性关节炎、癌症、脑卒中或心脏病的再灌注或缺血、自身免疫性疾病和其他疾病。本发明还涉及其制备的中间体、含有它们的制药组合物和它们的药用用途。
• [EN] NOVEL PROCESSES AND INTERMEDIATES FOR PREPARING TRIAZOLO-PYRIDINES<br/>[FR] NOUVEAUX PROCEDES ET PRODUITS INTERMEDIAIRES POUR PREPARER DES TRIAZOLO-PYRIDINES
  申请人：PFIZER PROD INC

  公开号：WO2004020438A3

  公开（公告）日：2004-07-22